TRFA TRAFALGAR INTERNATIONAL, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1695473 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY221.7%
TTM EPS YoY274.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA6,559.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11,026.1%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.05x
Accruals ratio6,862.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $12,630 |
| Cost of revenue | — | — | — | — | $12,655 |
| Gross profit | — | — | — | — | -$25 |
| Operating income | -$183,005 | -$156,276 | -$175,364 | -$177,035 | -$343,146 |
| Pretax income | -$331,612 | -$179,041 | -$188,402 | -$360,268 | -$602,226 |
| Net income | -$331,612 | -$179,041 | -$188,402 | -$360,268 | -$602,226 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 824,984 | 536,622 | 755.15M | 587.77M | 489.50M |
| Balance sheet | |||||
| Cash & equivalents | $815 | $57,368 | $166,859 | $270,030 | $377,520 |
| Current assets | $815 | $57,368 | $166,859 | $270,030 | $377,520 |
| Total assets | $815 | $57,785 | $172,276 | $280,447 | $392,937 |
| Current liabilities | $742,464 | $898,058 | $833,508 | $825,277 | $861,999 |
| Total liabilities | $742,464 | $898,058 | $833,508 | $825,277 | $861,999 |
| Shareholders' equity | -$741,649 | -$840,273 | -$661,232 | -$544,830 | -$469,062 |
| Shares outstanding | 944,935 | 536,622 | 804.64M | 732.64M | 508.64M |
| Cash flow statement | |||||
| Operating cash flow | -$60,153 | -$109,491 | -$103,171 | -$107,490 | -$235,433 |
| Financing cash flow | $3,600 | — | — | — | $500,000 |
| Stock-based compensation | $1,800 | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.